|
 |
European Pharmaceutical Contractor
|
Where has the Organisation Gone from Which we are Supposed to Achieve Excellence?
In the early 1980s two books, In Search of Excellence (1) and The Change Masters (2) became required reading for those training to become managers. Words such as 'champions', 'teams', 'task forces' and 'quality circles' were used to describe successful organisational behaviour where autonomy and entrepreneurship were encouraged. Kanter, author of The Change Masters, emphasised knowledge and teamwork and described one of her most successful companies as having organisational charts resembling a "plate of spaghetti". These books heralded a stream of management theory which transformed the working of large organisations into flatter, more team-based cultures with powerful educational programmes designed to empower individuals to 'add value'.
The natural extension of empowerment and organisational entrepreneurship was the devolution of companies to form networks of independent companies. In the pharmaceutical industry, the constant need to grow asset values led to mega mergers. The need to cut costs in these vast companies, in turn, led to an outsourcing model where companies either transferred their clinical research staff to large CROs with whom they set up preferred partnerships, or offered redundancy payments which often funded smaller organisations. The latest of these mega mergers, Pfizer's acquisition of Pharmacia, will result in another round of redundancies, spin-offs and staff transfers to what are now mega CROs (3). The organisation as we knew it no longer exists.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
